Uppsala, Sweden, October 14, 2024. Dicot Pharma announces today that the company has received Notice of Allowance for two US patent applications from the US Patent and Trademark Office (USPTO). These include, among other things, the active substance in LIB-01. A Notice of Allowance means that the USPTO intends to grant a patent once certain formal steps have been taken.
Recently, Dicot Pharma announced that it received a Notice of Allowance from the USPTO regarding a patent application (No. 18/496,049) covering key steps in the manufacture of the active substance in LIB-01. Today, the company announces that it has received Notice of Allowance for two additional patent applications (No. 18/469,860 and No. 18/496,043, respectively). All three of these patent applications belong to the same patent family in the United States named “New Compounds And Methods Of Their Manufacturing”.
The company is of the opinion that this patent family will provide very strong protection for manufacturing processes as well as the active substance in LIB-01 in USA. Once granted, the patents will be in force until the year 2042.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot’s strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot Pharma is listed on Spotlight Stock Market and has approximately 7,200 shareholders. For more information, please visit www.dicotpharma.com.
This disclosure contains information that Dicot Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14-10-2024 15:07 CET.